Alpha Centric Advisors LLC Incyte Corp Transaction History

Alpha Centric Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 08, 2022	SELL	$66.18 - $82.86 $1.32 Million - $1.66 Million	-20,000 Closed	0 $0
Q4 2021 Feb 25, 2022	BUY	$63.34 - $74.11 $300,865 - $352,022	4,750 Added 31.15%	20,000 $1.47 Million
Q3 2021 Mar 09, 2022	BUY	$68.67 - $84.02 $772,537 - $945,225	11,250 Added 281.25%	15,250 $1.05 Million
Q2 2021 Mar 09, 2022	SELL	$79.87 - $87.53 $179,707 - $196,942	-2,250 Reduced 36.0%	4,000 $337,000
Q1 2021 Mar 09, 2022	BUY	$76.02 - $100.5 $285,075 - $376,875	3,750 Added 150.0%	6,250 $508,000
Q4 2020 Mar 11, 2022	BUY	$80.74 - $97.7 $201,850 - $244,250	2,500 New	2,500 $217,000

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Centric Advisors LLC with notifications on news.